by | Jun 12, 2026 | Uncategorized
Eli Lilly’s $2.75B AI deal with Insilico Medicine targets age-related diseases. How AI is transforming longevity drug discovery and what it means for patients.
by | Jun 12, 2026 | Uncategorized
Pfizer and Valneva announced Phase 3 VALOR trial results for Lyme disease vaccine PF-07307405 on March 23, 2026: 73.2–74.8% efficacy in ages 5 and older. Regulatory submissions planned for 2026. No Lyme vaccine has been available in the U.S. since 2002.
by | Jun 12, 2026 | Uncategorized
The CDC issued a Health Advisory on April 2, 2026 warning that medetomidine, a veterinary sedative, is now detected in fentanyl samples across 18 states and D.C. Detections rose 3,000% between 2023 and 2025. Naloxone does not reverse its effects, and withdrawal can...
by | Jun 12, 2026 | Uncategorized
USDA FSIS public health alert (May 24, 2026) and genetic confirmation (June 1, 2026): E. coli O157:H7 outbreak linked to beef kofta at The Kebab Shop in California. Nine sick, five hospitalized, two children with HUS. Olympia Foods confirmed as source.
by | Jun 12, 2026 | Uncategorized
Cytisinicline, a plant-based alkaloid for smoking cessation, has an FDA PDUFA date of June 20, 2026 — 8 days away. If approved, it would be the first new quit-smoking drug in 20 years. Phase 3 ORCA-2 and ORCA-3 trials showed significantly higher quit rates than...
Recent Comments